277 unknown, 76 completed, 68 recruiting, 34 not yet recruiting. 380 Phase 2, 63 Phase 3, 62 Phase 1, 27 Not applicable, 8 Phase 4.
Follow apatinib: new trials by email Literature Review of apatinib trials Research Report on apatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer Apatinib Mesylate Tablets - Gastric Cancer, Surgery | Phase 3 | Not yet recruiting | Fujian Medical University | 118 | 2026-12-25 | 2026-01-02 |
| Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC Retlirafusp alfa, zeprumetostat, apatinib - Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 55 | 2026-10-01 | 2026-10-14 |
| GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC SHR-1701, Apatinib, gemcitabine - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 45 | 2026-09-10 | 2026-09-03 |
| Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer Retlirafusp Alfa, Apatinib, Fluoropyrimidine-Based Chemotherapy - Pancreatic Cancer | Phase 2 | Not yet recruiting | Tang-Du Hospital | 37 | 2026-08-30 | 2026-08-19 |
| A Study of Combination Therapy in Patients With Resectable Liver Cancer Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib - Liver Cancer (Primary and Metastatic) | Phase 2 | Not yet recruiting | Affiliated Hospital of Guangdong Medical University | 68 | 2026-08-01 | 2026-07-06 |
| SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma Retlirafusp alfa Injection, apatinib - Advanced Unresectable Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 80 | 2026-08-01 | 2026-08-06 |
| A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma SHR-8068 Injection, Adebrelimab Injection, Apatinib Mesylate Tablets - Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk | Phase 2 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 120 | 2026-07-01 | 2026-07-02 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
| Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation Long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib - Rectal Cancer Patients | Phase 2 | Active not recruiting | Harbin Medical University | 43 | 2026-05-29 | 2026-07-07 |
| A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC - HCC - Hepatocellular Carcinoma | Not applicable | Not yet recruiting | Henan Cancer Hospital | 208 | 2026-05-25 | 2026-06-01 |
| A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care - HCC | Phase 2 / Phase 3 | Recruiting | Guangzhou Virotech Pharmaceutical Co., Ltd. | 66 | 2026-05-13 | 2026-05-15 |
| Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer Retlirafusp alfa + Apatinib + Nab-paclitaxel - Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 50 | 2026-05-05 | 2026-05-28 |
| SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer SHR-1701, apatinib, S-1 & Oxaliplatin - Gastric Adenocarcinoma | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 80 | 2026-04-03 | 2026-07-16 |
| Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma Liposomal Irinotecan, Apatinib in arm1 - Osteosarcoma, Osteosarcoma Metastatic | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 56 | 2026-03-05 | 2026-03-18 |
| FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib - Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 86 | 2026-02-01 | 2026-01-20 |
| Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD Adebrelimab Injection, Apatinib Mesylate Tablets - Small Cell Lung Carcinoma | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 44 | 2026-01-31 | 2026-01-22 |
| A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer Trifluridine/Tipiracil (TAS-102) combined with Apatinib - Advanced Gastric Cancer | Not applicable | Not yet recruiting | Anhui Provincial Cancer Hospital | 30 | 2026-01-08 | 2026-01-28 |
| Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study The triple-therapy strategy of Ivarmacitinib, Apatinib, and Camrelizumab - Hepatocellular Carcinomas, Resistance to Immunotherapy | Phase 2 | Not yet recruiting | First Affiliated Hospital of Chongqing Medical University | 65 | 2026-01-01 | 2026-01-07 |
| SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure SHR-1701+Rivoceranib + SHR-2554, SHR-1701 + Rivoceranib - Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Jingdong Zhang | 40 | 2026-01-01 | 2025-12-31 |
| A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma Apatinib, Camrelizumab, TACE - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Zhongshan Hospital | 222 | 2025-12-22 | 2025-12-30 |
Showing 20 of 502. Sign in to see all of them.
Stomach Neoplasms (58) · Carcinoma, Hepatocellular (46) · Carcinoma, Non-Small-Cell Lung (23) · Small Cell Lung Carcinoma (19) · Breast Neoplasms (18) · Colorectal Neoplasms (18) · Ovarian Neoplasms (18) · Neoplasms (14) · Sarcoma (14) · Triple Negative Breast Neoplasms (13) · Cholangiocarcinoma (11) · Esophageal Squamous Cell Carcinoma (11) · Nasopharyngeal Carcinoma (11) · Lung Neoplasms (10) · Esophageal Neoplasms (9)
Jiangsu HengRui Medicine Co., Ltd. (37) · Sun Yat-sen University (29) · Fudan University (23) · Tianjin Medical University Cancer Institute and Hospital (18) · Henan Cancer Hospital (16) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (15) · Fujian Cancer Hospital (14) · Peking Union Medical College Hospital (12) · Peking University Cancer Hospital & Institute (10) · Shanghai Zhongshan Hospital (10) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (9) · Chinese Academy of Medical Sciences (8) · Elevar Therapeutics (7) · Peking University People's Hospital (7) · West China Hospital (7)
China (411) · South Korea (9) · United States (9) · Germany (3) · Italy (3) · Poland (3) · Taiwan (3) · France (2) · Hong Kong (2) · Japan (2) · Russia (2) · Spain (2) · Turkey (Türkiye) (2) · Ukraine (2) · United Kingdom (2)
Wei Deng, M.D. (3) · Binghe Xu (2) · Chenping Zhang, M.D. (2) · Chunmei Bai (2) · Han Liang, Master (2) · Jin Li (2) · Jin Li, MD, PHD (2) · Jun Zhou (2) · Li Xiao, Doctor (2) · Rongbo Lin (2) · Shukui Qin, MD (2) · Wei Guo, M.D. (2) · Wei Jiang, Ph.D. (2) · Xiaohui He, B.D. (2) · Xin Huang, MD (2)
PMID 26884585, PMID 23918952, PMID 18172173, PMID 18971936, PMID 20923544, PMID 21183517, PMID 21296855, PMID 21742485, PMID 24292957, PMID 32376724, PMID 32448804, PMID 37580352, PMID 38271925, PMID 39924483, PMID 12826431, PMID 14745444, PMID 15864277, PMID 17018256, PMID 17105988, PMID 17949799, PMID 19331206, PMID 20375404, PMID 20876799, PMID 21443688, PMID 22212563, PMID 23464465, PMID 23510598, PMID 24024839, PMID 24140268, PMID 24307987, PMID 24472472, PMID 24484722, PMID 24500024, PMID 24511038, PMID 24581682, PMID 24607285, PMID 24637997, PMID 24950987, PMID 25299232, PMID 25366685, PMID 25376790, PMID 25862517, PMID 26020064, PMID 26341920, PMID 26755520, PMID 28027849, PMID 28352185, PMID 28444622, PMID 28596446, PMID 28935273
2023 (1)